Evidence map›Paper›PMID 42758356›Full record

ArticleJournal of computer-aided molecular design2026

Identification of potential SARS-CoV-2 M

Aunlika Chimprasit, Guillaume Bret, Supa Hannongbua, Patchreenart Saparpakorn, Didier Rognan

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aunlika ChimprasitDepartment of Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok, 10900, Thailand.
Guillaume BretLaboratoire d'Innovation Thérapeutique, UMR7200 CNRS-Université de Strasbourg, 67400, Illkirch, France.
Supa HannongbuaDepartment of Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok, 10900, Thailand.
Patchreenart SaparpakornDepartment of Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok, 10900, Thailand. fscipnsk@ku.ac.th.ORCID https://orcid.org/0000-0001-7980-1473
Didier RognanLaboratoire d'Innovation Thérapeutique, UMR7200 CNRS-Université de Strasbourg, 67400, Illkirch, France. rognan@unistra.fr.

Funding

Kasetsart University Research and Development Institute FF(KU-SRIU)13.67
6 · The paper itself

Abstract

The SARS-CoV-2 main protease (M

Indexed as

Antiviral AgentsBiological ProductsProtease InhibitorsViral Nonstructural ProteinsBinding SitesCoronavirus 3C ProteasesCOVID-19HumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingSARS-CoV-2ThailandAntiviral AgentsBiological ProductsCoronavirus 3C ProteasesLigandsProtease InhibitorsViral Nonstructural ProteinsMain proteaseNon-covalent inhibitorsProtein–ligand interactions fingerprintSARS-CoV-2

Identifiers

PMID42758356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.